Randomized Placebo-Controlled First-in-Human Study With GNbAC1.
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2012
Price : $35 *
At a glance
- Drugs Temelimab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; First in man
- 13 Oct 2012 Results presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
- 12 Oct 2012 New trial record